Download PDF
Drug Res (Stuttg) 2017; 67(05): 302-307
DOI: 10.1055/s-0043-100386
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Effect of a Bicyclic Pyrimidine Derivative (KRP-103), a Novel Selective Tachykinin NK1 Receptor Antagonist, on Bladder Function in Guinea Pigs

Asao Tanioka
1   Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan
2   Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan
,
Takashi Deguchi
1   Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
07 March 2017 (online)

Also available at
    Permissions and Reprints

Abstract

We evaluated the pharmacological characteristics of KRP-103, chemically named as ((2-(4-acetylpiperazin-1-yl)-6-[3,5-bis(trifluorometheyl)-phenylmethyl]-4- (2-methylphenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one), and its effects on lower urinary tract function in guinea pigs. In radioligand binding assay, KRP-103 showed higher selectivity for human NK1 receptor (hNK1R) than for human NK2 receptor (hNK2R) and human NK3 receptor (hNK3R) (Ki for hNK1R, hNK2R and hNK3R=0.126 nM, > 10 000 nM and > 10 000 nM). In distention-induced rhythmic bladder contractions (RBCs) in urethane-anesthetized guinea pigs, intravenous administration of KRP-103 dose-dependently increased the shutdown time of RBCs and slightly decreased the amplitude of RBCs (only about 20%). In acutely spinalized guinea pig cystometory, intraduodenal administration of KRP-103 dose-dependently increased the effective bladder capacity with a minimum effective dose of 1 mg/kg. Furthermore, to clarify the site of action of KRP-103, we evaluated the inhibitory effects of KRP-103 on bladder contractions induced by electrical stimulation (ES) of the central or peripheral cut end of the pelvic nerve (PN). KRP-103 inhibited the bladder contractions induced by ES of the central cut end of PN but not those induced by ES of the peripheral cut end of PN. These results indicate that KRP-103 enhances bladder storage function by inhibiting sensory transmission from the bladder at the level of spinal cord without affecting bladder efferent function, suggesting that KRP-103 may be a suitable therapeutic drug for treatment of overactive bladder.

Key words

overactive bladder - KRP-103 - tachykinin NK1 receptor antagonist - micturition reflex - bladder capacity
 

  • References

  • 1 Haylen BT, De Ridder D, Freeman RM. et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010; 21: 167-178
    PubMedGoogle Scholar
  • 2 Abrams P, Cardozo L, Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178
    CrossrefPubMedGoogle Scholar
  • 3 Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU international 2005; 96: 1314-1318
    CrossrefPubMedGoogle Scholar
  • 4 Stewart WF, Van Rooyen JB, Cundiff GW. et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-336
    CrossrefPubMedGoogle Scholar
  • 5 Milsom I, Abrams P, Cardozo L. et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU international 2001; 87: 760-766
    CrossrefPubMedGoogle Scholar
  • 6 Coyne KS, Sexton CC, Kopp ZS. et al. The impact of overactive bladder on mental health, work productivity and health-related quolity of life in UK and Sweden: results from EpiLUTS study. BJU international 2011; 108: 1459-1471
    CrossrefPubMedGoogle Scholar
  • 7 Irwin DE, Milson I, Kopp ZS. et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six Europian countries. BJU international 2006; 97: 96-100
    CrossrefPubMedGoogle Scholar
  • 8 Liberman JN, Hunt TL, Stewart WF. et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 1044-1050
    CrossrefPubMedGoogle Scholar
  • 9 Basra RK, Wagg A, Chapple C. et al. A review of adherence to drug therapy in patients with overactive bladder. BJU international 2008; 102: 774-779
    CrossrefPubMedGoogle Scholar
  • 10 Sears CL, Lewis C, Noel K. et al. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010; 183: 1077-1081
    CrossrefPubMedGoogle Scholar
  • 11 Wagg A, Compion G, Fahey A. et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU international 2012; 110: 1767-1774
    CrossrefPubMedGoogle Scholar
  • 12 Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Advances in urology. 2011;
    PubMed
  • 13 Chapple CR, Khullar V, Gabriel Z. et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54: 543-562
    CrossrefPubMedGoogle Scholar
  • 14 Hokfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med. 2001; 249: 27-40
    PubMedGoogle Scholar
  • 15 Jancso G, Maggi CA. Distribution of capsaicin-sensitive urinary bladder afferents in the rat spinal cord. Brain res 1987; 418: 371-376
    CrossrefPubMedGoogle Scholar
  • 16 Charlton CG, Helke CJ. Autoradiographic localization and characterization of spinal cord substance P binding sites: high densities in sensory, autonomic, phrenic, and Onuf’s motor nuclei. J. Neurosci. 1985; 5: 1653-1661
    CrossrefPubMedGoogle Scholar
  • 17 Yashpal K, Dam TV, Quirion R. Quantitative autoradiographic distribution of multiple neurokinin binding sites in rat spinal cord. Brain res 1990; 506: 259-266
    CrossrefPubMedGoogle Scholar
  • 18 Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept. 2001; 101: 1-18
    CrossrefPubMedGoogle Scholar
  • 19 Zagorodnyuk VP, Costa M, Brookes SJ. Major classes of sensory neurons to the urinary bladder. Autonom Neurosci Basic Cli 2006; 126: 390-397
    PubMedGoogle Scholar
  • 20 Morrison J. The activation of bladder wall afferent nerves. Experimental Physiology. 1999; 84: 131-136
    CrossrefPubMedGoogle Scholar
  • 21 Duggan AW, Hendry IA. Laminar localization of release of immunoreactive substance P in the dorsal horn with antibody-coated microelectrodes. Neurosci Lett. 1986; 68: 134-140
    CrossrefPubMedGoogle Scholar
  • 22 Littlewood NK, Todd AJ, Spike RC. et al. The types of neuron in spinal dorsal horn which possess neurokinin-1 receptors. Neuroscience 1995; 66: 597-608
    CrossrefPubMedGoogle Scholar
  • 23 McCarson KE, Goldstein BD. Release of substance P into the superficial dorsal horn following nociceptive activation of the hindpaw of the rat. Brain Res. 1991; 568: 109-115
    CrossrefPubMedGoogle Scholar
  • 24 Sculptoreanu A, de Groat WC. Neurokinins enhance excitability in capsaicin-responsive DRG neurons. Exp Neurol. 2007; 205: 92-100
    CrossrefPubMedGoogle Scholar
  • 25 Avelino A, Cruz F. Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desenstization by capsaicin or resiniferatoxin. Auton Neurosci 2000; 86: 37-46
    CrossrefPubMedGoogle Scholar
  • 26 Silva C, Silva J, Ribeiro MJ. et al. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Uror 2005; 48: 650-655
    PubMedGoogle Scholar
  • 27 Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999; 162: 3-11
    CrossrefPubMedGoogle Scholar
  • 28 Seto S, Tanioka A, Ikeda M. et al. Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists. Bioorg. Med. Chem. Lett. 2005; 13: 5717-5732
    CrossrefPubMedGoogle Scholar
  • 29 Kobayashi F, Yageta Y, Segawa M. et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in morris water maze test. Arzneimittelforschung 2007; 57: 147-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Kamo I, Imai S, Okanishi S. et al. Possible site of action of TAK-637, a tachykinin NK1 receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol. 2000; 401: 235-240
    CrossrefPubMedGoogle Scholar
  • 31 Maggi CA, Giuliani S, Santicioli P. et al. Species related variations in the effect of capsaicin on urinary bladder functions: relation to bladder content of substance P-like immunoreactivity. Naunyn-Schmiedeberg’s Arch Pharmacol 1987; 336: 546-555
    PubMedGoogle Scholar
  • 32 Palea S, Pietra C. Involvement of spinal NK1 and opioids receptors in modulating the inhibitory effect of capsaicin on micturition reflex in the acute spinalized guinea pig. J Urol. 1999; 161: 998-1005
    CrossrefPubMedGoogle Scholar
  • 33 Beresford IJM, Birch PJ, Hagan RM. et al. Investigation into species variants in tachykinin NK1 receptors by use of the nonpeptide antagonist, CP-96,345. Br J Pharmacol. 1991; 104: 292-293
    CrossrefPubMedGoogle Scholar
  • 34 Gitter BD, Bruns RF, Howbert JJ. et al. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J Pharmacol Exp Ther. 1995; 275: 737-744
    PubMedGoogle Scholar
  • 35 Fong TM, Yu H, Strader CD. Molecular basis for the species selectivity of neurokinin-1 receptor antagonist CP-96,345 and RP67580. J Biol Chem. 1992; 267: 25668-25671
    PubMedGoogle Scholar
  • 36 Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol. 1999; 375: 51-60
    CrossrefPubMedGoogle Scholar
  • 37 Peterson JS, Hanson RC, Noronha-Blob L. In vivo cystometrogram studies in urethane-anaesthetized and in conscious guinea pigs. J Pharmacol Methods 1989; 21: 231-241
    CrossrefPubMedGoogle Scholar
  • 38 Doi T, Kamo I, Imai S. et al. Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol. 2000; 395: 241-246
    CrossrefPubMedGoogle Scholar
  • 39 Ishizuka O, Igawa Y, Lecci A. et al. Role of intrathecal tachykinins for micturition in unanesthetized rats with and without bladder outlet obstraction. Br J Pharmacol. 1994; 113: 111-116
    CrossrefPubMedGoogle Scholar
  • 40 Seki S, Erickson KA, Seki M. et al. Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Renal Physiol 2005; 288: F466-F473
    CrossrefPubMedGoogle Scholar
  • 41 Verhamme KM, Sturkenboom MC, Stricker BH. et al. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008; 31: 373-388
    CrossrefPubMedGoogle Scholar
  • 42 Lecci A, Giuliani S, Garret C. et al. Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex. Neuroscience 1993; 54: 827-837
    CrossrefPubMedGoogle Scholar
  • 43 Doyle CA, Hunt SP. Substance P receptor (neurokinin-1)-expressing neurons in laminae I of the spinal cord for the intensity of noxious stimulation: a c-fos study in rat. Neuroscience 1999; 89: 17-28
    CrossrefPubMedGoogle Scholar
  • 44 Zhang X, Pietra C, Lovati E. et al. Activation of neurokinin-1 receptors increases the excitability of guinea pig dorsal root ganglion cells. J Pharmacol Exp Ther. 2012; 343: 44-52
    CrossrefPubMedGoogle Scholar